SEC Tracker
Get the app

Iridex IRIX

Iridex FY 2024: revenue $48.7M, down 6%; diluted EPS −$0.54

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Iridex reported for the year ended Dec 28, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$48.7M−6% from $51.9M in FY 202310-K income statement, on EDGAR
  2. Net income−$8.9MAgainst −$9.6M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS−$0.54Against −$0.59 in FY 202310-K income statement, on EDGAR
  4. Cash and cash equivalents$2.4M−66% from $7.0M in FY 202310-K balance sheet, on EDGAR
  5. Cash from operations−$7.3MAgainst −$6.7M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Iridex files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3845 and related industry codes: the same peer list as the financial tables.

  1. Nexalin Technology NXL public float $15M, Jun 30, 2025
  2. Biotricity BTCY public float $13M, Sep 30, 2025
  3. Beyond Air XAIR public float $16M, Sep 30, 2025
  4. RetinalGenix Technologies RTGN public float $16M, Jun 30, 2025
  5. Harvard Apparatus Regenerative Technology HRGN public float $16M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.